Polymyositis Pipeline, Clinical Trials Assessment 2023 (Updated) | Companies - Janssen Pharmaceutical, PAEAN Biotechnology, Kezar Life Sciences, Roche, Restem, Viela Bio, Bristol-Myers Squibb, ImmunoForge, and others

DelveInsight's, "Polymyositis Pipeline Insight 2023" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in the Polymyositis pipeline landscape. It covers the Polymyositis pipeline drug profiles, including Polymyositis clinical trials and nonclinical stage products. It also covers the Polymyositis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Polymyositis Pipeline treatment landscape of the report, click here @ Polymyositis Pipeline Outlook- https://www.delveinsight.com/report-store/polymyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Polymyositis Pipeline Report
• DelveInsight's Polymyositis Pipeline report depicts a robust space with 7+ active players working to develop 7+ pipeline therapies for Polymyositis.
• The leading Polymyositis Companies include Janssen Pharmaceutical, PAEAN Biotechnology, Kezar Life Sciences, Roche, Restem, Viela Bio, Bristol-Myers Squibb, ImmunoForge, and others
• Promising Polymyositis Pipeline Therapies include GB-0998, Tacrolimus, Brepocitinib, human immunoglobulin G, Lenabasum 20 mg, Octagam 10%, Infliximab, H.P. Acthar Gel, Ravulizumab, and others
• Merck is now in Phase II of the clinical development of Enpatoran for Dermatomyositis. GlobalData estimates that a 60% phase transition success rate (PTSR) indication benchmark is required for Phase II medicines for Dermatomyositis to advance to Phase III.
• Brepocitinib is being developed by Priovant for the treatment of severe autoimmune illnesses that have few licenced treatments and in which simultaneous inhibition of TYK2 and JAK1 may be more effective than either inhibition alone.

For further information, refer to the detailed Polymyositis Unmet Needs, Polymyositis Market Drivers, and Polymyositis Market Barriers, click here for Polymyositis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/polymyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Polymyositis Overview
Polymyositis is a type of inflammatory myopathy, which refers to a group of muscle diseases characterized by chronic muscle inflammation and weakness. The muscles affected by Polymyositis are the skeletal muscles (those involved with making movements) on both sides of the body. The disease is more common among women and among black individuals. The exact cause of Polymyositis is unknown. The disease shares many characteristics with autoimmune disorders, which occur when the immune system mistakenly attacks healthy body tissues.

Request a sample and discover the recent advances in Polymyositis Ongoing Clinical Trial Analysis and Medications, click here @ Polymyositis Treatment Landscape- https://www.delveinsight.com/sample-request/polymyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Polymyositis Emerging Drugs

• Ustekinumab: Janssen Pharmaceutical
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin (IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. Currently, it is in Phase III stage of clinical trial evaluation to treat Polymyositis.

• PN-101: PAEAN Biotechnology
PN-101 the world's first allogeneic mitochondrial drug candidate for the treatment of polymyositis and dermatomyositis. PN-101 is the first-in-class drug where the main component consists of mitochondria isolated from stem cells. Currently, it is in Phase I/II stage of clinical trial evaluation to treat Polymyositis.

Dive deep into rich insights for drugs for Polymyositis Market Drivers and Polymyositis Market Barriers, click here @ Polymyositis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/polymyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Polymyositis Pipeline Therapeutics Assessment
There are approx. 7+ key companies which are developing the therapies for Polymyositis. The companies which have their Polymyositis drug candidates in the most advanced stage, i.e. phase III include, Janssen Pharmaceutical.

Scope of the Polymyositis Pipeline Report
• Coverage- Global
• Polymyositis Companies- Janssen Pharmaceutical, PAEAN Biotechnology, Kezar Life Sciences, Roche, Restem, Viela Bio, Bristol-Myers Squibb, ImmunoForge, and others
• Polymyositis Pipeline Therapies- GB-0998, Tacrolimus, Brepocitinib, human immunoglobulin G, Lenabasum 20 mg, Octagam 10%, Infliximab, H.P. Acthar Gel, Ravulizumab, and others
• Polymyositis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Polymyositis Mergers and acquisitions, Polymyositis Licensing Activities @ Polymyositis Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/polymyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Polymyositis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Polymyositis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Ustekinumab: Janssen Pharmaceutical
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. PN-101: PAEAN Biotechnology
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Polymyositis Key Companies
21. Polymyositis Key Products
22. Polymyositis- Unmet Needs
23. Polymyositis- Market Drivers and Barriers
24. Polymyositis- Future Perspectives and Conclusion
25. Polymyositis Analyst Views
26. Polymyositis Key Companies
27. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.